CO2020009091A2 - Exosomas para inmunooncología y terapia antiinflamatoria - Google Patents
Exosomas para inmunooncología y terapia antiinflamatoriaInfo
- Publication number
- CO2020009091A2 CO2020009091A2 CONC2020/0009091A CO2020009091A CO2020009091A2 CO 2020009091 A2 CO2020009091 A2 CO 2020009091A2 CO 2020009091 A CO2020009091 A CO 2020009091A CO 2020009091 A2 CO2020009091 A2 CO 2020009091A2
- Authority
- CO
- Colombia
- Prior art keywords
- exosomes
- oncology
- immuno
- inflammatory therapy
- extracellular vesicles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En la presente, se describen vesículas extracelulares que comprenden un componente inmunomodulador. También se proporcionan métodos para producir las vesículas extracelulares y métodos para usar las vesículas extracelulares para tratar el cáncer, la EICH y las enfermedades autoinmunitarias.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762611140P | 2017-12-28 | 2017-12-28 | |
US201862723267P | 2018-08-27 | 2018-08-27 | |
PCT/US2018/068062 WO2019133934A2 (en) | 2017-12-28 | 2018-12-28 | Exosomes for immuno-oncology and anti-inflammatory therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020009091A2 true CO2020009091A2 (es) | 2020-12-21 |
Family
ID=67058801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0009091A CO2020009091A2 (es) | 2017-12-28 | 2020-07-23 | Exosomas para inmunooncología y terapia antiinflamatoria |
Country Status (16)
Country | Link |
---|---|
US (3) | US10723782B2 (es) |
EP (1) | EP3731849A4 (es) |
JP (2) | JP2021508691A (es) |
KR (1) | KR20200108275A (es) |
CN (1) | CN111655271A (es) |
AU (1) | AU2018394238A1 (es) |
BR (1) | BR112020013131A2 (es) |
CA (1) | CA3085471A1 (es) |
CL (1) | CL2020001691A1 (es) |
CO (1) | CO2020009091A2 (es) |
EA (1) | EA202091134A1 (es) |
IL (1) | IL275600A (es) |
MX (1) | MX2020006672A (es) |
PH (1) | PH12020550805A1 (es) |
SG (1) | SG11202005049QA (es) |
WO (1) | WO2019133934A2 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
MX2020006672A (es) | 2017-12-28 | 2020-08-31 | Codiak Biosciences Inc | Exosomas para inmunooncologia y terapia antiinflamatoria. |
EP3765485A4 (en) * | 2018-03-12 | 2022-05-18 | Board of Regents, The University of Texas System | IMMUNOEXOSOMES AND METHODS OF USE THEREOF |
JP7416433B2 (ja) | 2018-04-10 | 2024-01-17 | ノースウェスタン ユニバーシティ | 標的指向性親和性ドメインに基づく膜タンパク質を含む細胞外小胞 |
US20220323506A1 (en) * | 2019-06-04 | 2022-10-13 | Thomas Jefferson University | Oligodendrocyte-derived Extracellular Vesicles for Therapy of Multiple Sclerosis |
WO2021003425A1 (en) * | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Methods of inducing hematopoiesis |
WO2021062060A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour |
EP4034081A1 (en) * | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Extracellular vesicle compositions |
WO2021076808A1 (en) * | 2019-10-15 | 2021-04-22 | Cornell University | Methods for detecting and inhibiting brain metastasis |
WO2021146616A1 (en) | 2020-01-17 | 2021-07-22 | Codiak Biosciences, Inc. | Cholesterol assays for quantifying extracellular vesicles |
EP3858332A1 (en) | 2020-01-31 | 2021-08-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bottom-up assembly of synthetic extracellular vesicles |
EP4099984A4 (en) * | 2020-02-05 | 2024-05-01 | Diadem Biotherapeutics Inc | ARTIFICIAL SYNAPSES |
AU2021272903A1 (en) * | 2020-05-11 | 2022-11-10 | Strm.Bio Incorporated | Compositions and methods related to megakaryocyte-derived extracellular vesicles |
KR102341138B1 (ko) * | 2020-05-31 | 2021-12-21 | 주식회사 엑소코바이오 | 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법 |
EP4171596A1 (en) | 2020-06-24 | 2023-05-03 | Chameleon Biosciences, Inc. | Extracellular vesicles with immune modulators |
JP2023538077A (ja) * | 2020-08-17 | 2023-09-06 | コディアック バイオサイエンシーズ, インコーポレイテッド | がんの治療方法 |
EP4209599A1 (en) * | 2020-09-04 | 2023-07-12 | Daegu Gyeongbuk Institute Of Science and Technology | Method for screening immunogenic anticancer activity cytokine, and composition for preventing or treating cancer disease, comprising il-15 as active ingredient |
WO2022140438A1 (en) * | 2020-12-22 | 2022-06-30 | Verily Life Sciences Llc | Methods for assaying target proteins on extracellular vesicles in plasma |
CN112646781B (zh) * | 2020-12-25 | 2023-07-25 | 广东省人民医院 | 一种包含人ace2蛋白的外泌体及其应用 |
CN113040877B (zh) * | 2021-03-11 | 2022-07-22 | 上海市东方医院(同济大学附属东方医院) | 一种基于筋膜间隙理念治疗腹部疾病的输注外泌体系统 |
CN113462645B (zh) * | 2021-03-26 | 2023-11-28 | 上海瑞开投资管理有限公司 | 包含nk细胞和植物来源的外泌体的组合物、其用途及包含其的产品 |
WO2022215078A1 (en) * | 2021-04-07 | 2022-10-13 | Ramot At Tel-Aviv University Ltd. | Modified cannabinoids and uses thereof |
WO2022250880A1 (en) * | 2021-05-25 | 2022-12-01 | Malcolm Thomas | Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases |
AU2022315530A1 (en) | 2021-07-20 | 2024-01-18 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
WO2023021150A1 (en) * | 2021-08-18 | 2023-02-23 | Universität Duisburg-Essen | A biomarker indicating the therapeutic efficacy of extracellular vesicle (ev)-preparations |
CN113866413B (zh) * | 2021-09-29 | 2023-05-30 | 上海市同济医院 | 一种结直肠癌诊断标志物及其应用 |
WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
CN114561347A (zh) * | 2022-02-25 | 2022-05-31 | 和携科技有限公司 | 一种脂肪间充质干细胞的培养基和培养方法 |
WO2023195570A1 (ko) * | 2022-04-08 | 2023-10-12 | 이왕재바이오연구소 주식회사 | 슈퍼옥시드 디스무타아제를 포함하는 항암 조성물 |
CN114807023B (zh) * | 2022-04-29 | 2024-03-15 | 中山大学·深圳 | 一种细胞膜囊泡及其制备方法与应用 |
CN114763533B (zh) * | 2022-05-17 | 2024-02-23 | 深圳市第二人民医院(深圳市转化医学研究院) | 外泌体表面原位生长纳米硒的方法及得到的硒化外泌体 |
WO2023229366A1 (en) * | 2022-05-24 | 2023-11-30 | Shiftbio Co., Ltd. | Surface-engineered extracellular vesicles and therapeutic uses thereof |
WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
CN115047186B (zh) * | 2022-06-15 | 2023-02-14 | 暨南大学 | 一种外泌体检测方法 |
EP4309660A1 (en) | 2022-07-18 | 2024-01-24 | Lietuvos Sveikatos Mokslu Universitetas | Extracellular vesicles and particles from immune cells for providing anticancer activity |
WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
CN117018217B (zh) * | 2023-10-10 | 2024-01-30 | 天津外泌体科技有限公司 | Gnai2作为细胞外囊泡支架蛋白的应用、细胞外囊泡及其制备方法和应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001093836A2 (en) | 2000-06-09 | 2001-12-13 | Teni Boulikas | Encapsulation of polynucleotides and drugs into targeted liposomes |
JP4662708B2 (ja) * | 2001-08-17 | 2011-03-30 | エクソセラ・エルエルシー | エクソゾームにタンパク質を標的化する方法および組成物 |
US7803906B2 (en) | 2002-03-22 | 2010-09-28 | Gene Signal International Sa | Composition comprising an angiogenesis related protein |
US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
EP3569254B1 (en) * | 2009-04-17 | 2022-07-20 | Oxford University Innovation Limited | Composition for delivery of genetic material |
WO2012048372A1 (en) | 2010-10-11 | 2012-04-19 | Medsaic Pty Ltd | Assay for disease detection |
AU2013201121A1 (en) * | 2011-09-20 | 2013-04-04 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
US9777042B2 (en) | 2011-12-15 | 2017-10-03 | Morehouse School Of Medicine | Method of purifying HIV/SIV Nef from exosomal fusion proteins |
EP2687219A1 (en) * | 2012-07-18 | 2014-01-22 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions |
AU2013347838A1 (en) | 2012-11-26 | 2015-06-11 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
EP3252160B1 (en) | 2012-12-12 | 2020-10-28 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
SG11201601939VA (en) * | 2013-09-16 | 2016-04-28 | Agency Science Tech & Res | Method |
KR20150043937A (ko) | 2013-10-15 | 2015-04-23 | 삼성전자주식회사 | 개체의 간암 진단용 조성물, 개체의 간암 진단하는 방법 및 개체의 간암 진단에 필요한 정보를 얻는 방법 |
CA2936100A1 (en) * | 2013-12-04 | 2015-06-11 | Board Of Regents, The University Of Texas System | Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis |
JP6353073B2 (ja) * | 2013-12-20 | 2018-07-04 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | 細胞回復のための組成物並びにその作製及び使用方法 |
US10772911B2 (en) * | 2013-12-20 | 2020-09-15 | Advanced ReGen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
AU2015330855A1 (en) | 2014-10-09 | 2017-04-27 | Celularity Inc. | Placenta-derived adherent cell exosomes and uses thereof |
IL294395A (en) * | 2014-10-27 | 2022-08-01 | Univ Central Florida Res Found Inc | Methods and compositions for natural killer cells |
WO2016077639A2 (en) | 2014-11-12 | 2016-05-19 | VL27, Inc. | Nanovesicular therapies |
US20180042847A1 (en) * | 2015-03-16 | 2018-02-15 | Duncan ROSS | Method of treatment comprising membrane-enclosed vesicle |
US10427129B2 (en) | 2015-04-17 | 2019-10-01 | LLT International (Ireland) Ltd. | Systems and methods for facilitating reactions in gases using shockwaves produced in a supersonic gaseous vortex |
WO2016168680A1 (en) * | 2015-04-17 | 2016-10-20 | Exocyte Therapeutics Pte Ltd. | Method for developing exosome-based vaccines |
WO2016187717A1 (en) * | 2015-05-26 | 2016-12-01 | Exerkine Corporation | Exosomes useful for genome editing |
KR102386735B1 (ko) * | 2015-11-06 | 2022-04-14 | 주식회사 제넥신 | 변형된 인터루킨-7 융합 단백질의 제형 |
MX2018011202A (es) | 2016-03-15 | 2019-03-28 | Codiak Biosciences Inc | Vesiculas de membrana terapeuticas. |
US20190125848A1 (en) * | 2016-03-30 | 2019-05-02 | Dana-Farber Cancer Institute, Inc. | Dendritic cell-extracellular vesicle fusions and methods of using same |
US20180128833A1 (en) * | 2016-11-08 | 2018-05-10 | Metaclipse Therapeutics Corporation | Methods of treating with tumor membrane vesicle-based immunotherapy and predicting therapeutic response thereto |
WO2019040920A1 (en) * | 2017-08-25 | 2019-02-28 | Codiak Biosciences, Inc. | PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS |
MX2020006672A (es) | 2017-12-28 | 2020-08-31 | Codiak Biosciences Inc | Exosomas para inmunooncologia y terapia antiinflamatoria. |
-
2018
- 2018-12-28 MX MX2020006672A patent/MX2020006672A/es unknown
- 2018-12-28 CA CA3085471A patent/CA3085471A1/en active Pending
- 2018-12-28 BR BR112020013131-8A patent/BR112020013131A2/pt unknown
- 2018-12-28 KR KR1020207016594A patent/KR20200108275A/ko not_active Application Discontinuation
- 2018-12-28 WO PCT/US2018/068062 patent/WO2019133934A2/en unknown
- 2018-12-28 CN CN201880083335.0A patent/CN111655271A/zh active Pending
- 2018-12-28 EA EA202091134A patent/EA202091134A1/ru unknown
- 2018-12-28 JP JP2020534610A patent/JP2021508691A/ja active Pending
- 2018-12-28 AU AU2018394238A patent/AU2018394238A1/en active Pending
- 2018-12-28 US US16/236,246 patent/US10723782B2/en active Active
- 2018-12-28 EP EP18895264.2A patent/EP3731849A4/en active Pending
- 2018-12-28 SG SG11202005049QA patent/SG11202005049QA/en unknown
-
2020
- 2020-06-04 PH PH12020550805A patent/PH12020550805A1/en unknown
- 2020-06-19 CL CL2020001691A patent/CL2020001691A1/es unknown
- 2020-06-23 IL IL275600A patent/IL275600A/en unknown
- 2020-07-06 US US16/921,351 patent/US20200407419A1/en active Pending
- 2020-07-23 CO CONC2020/0009091A patent/CO2020009091A2/es unknown
-
2022
- 2022-10-26 US US18/049,999 patent/US20240010705A1/en active Pending
-
2023
- 2023-08-01 JP JP2023125551A patent/JP2023133470A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018394238A1 (en) | 2020-06-18 |
JP2021508691A (ja) | 2021-03-11 |
CA3085471A1 (en) | 2019-07-04 |
US20200407419A1 (en) | 2020-12-31 |
MX2020006672A (es) | 2020-08-31 |
EP3731849A4 (en) | 2021-12-01 |
US20190202892A1 (en) | 2019-07-04 |
CL2020001691A1 (es) | 2020-11-13 |
SG11202005049QA (en) | 2020-07-29 |
US10723782B2 (en) | 2020-07-28 |
PH12020550805A1 (en) | 2021-05-31 |
WO2019133934A2 (en) | 2019-07-04 |
WO2019133934A3 (en) | 2019-08-29 |
JP2023133470A (ja) | 2023-09-22 |
KR20200108275A (ko) | 2020-09-17 |
EA202091134A1 (ru) | 2020-11-20 |
EP3731849A2 (en) | 2020-11-04 |
US20240010705A1 (en) | 2024-01-11 |
CN111655271A (zh) | 2020-09-11 |
IL275600A (en) | 2020-08-31 |
BR112020013131A2 (pt) | 2020-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
PH12018502429A1 (en) | Antibody molecules for cancer treatment | |
CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
CY1122227T1 (el) | Ρυθμιση δραστικοτητας συμπληρωματος | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
EA201692334A1 (ru) | Кортикостероидные композиции для местного применения | |
MX2018010993A (es) | Derivados de icariina e icaritina. | |
SV2019005822A (es) | Metodos para tratar el cáncer de próstata | |
MX2020001727A (es) | Terapia de combinacion. | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
CR20180080A (es) | Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas |